Vaginal Neoplasms
9
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Agnostic Therapy in Rare Solid Tumors
Image-guided Brachytherapy for Vaginal Cancer (EMBRAVE)
Peritoneum Vaginoplasty; Implementation According to IDEAL Framework
Impact of the COVID-19 Pandemic in Gynecological Oncology
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy
Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2)
Magnetic Resonance Imaging Guided Gynecologic Brachytherapy
Questionnaire Study for Gynecological Cancer Survivors